

## Pharmacy Oncology Symposium September 20th, 2025

### Agenda

- 7:30am – 7:55 am Registration and breakfast
- 8:00 am – 8:05 am Welcome/Greeting  
Jordan Scott, PharmD
- 8:00 – 9:00 am **Hazardous Drug Compounding in 2025: A Review of Current Standards**  
Dr. Dominic Lovria, PharmD, BCSCP
- **Objective #1:** Understand the core principles of USP
  - **Objective #2:** Understand the facility requirements for compounding sterile hazardous medications
- 9:00 – 9:30 am **Hodgkin's Therapeutics: Beyond the ABVD Baseline**  
Dr. Eugene Przespolewski, PharmD, BCOP
- **Objective #1:** Compare benefits of new treatment strategies for newly diagnosed Hodgkins lymphoma
  - **Objective #2:** Formulate recommendations for frontline management of Hodgkins lymphoma
  - **Objective #3:** Devise a treatment strategy for relapsed disease after immunotherapy failure
- 9:30 – 10:00 am **Social Determinants of Health and the Oncology Patient**  
Dr. Catherine Forbes, PharmD
- **Objective #1:** Recall the five domains of social determinants of health (SDOH)
  - **Objective #2:** Explain how SDOH affect care and outcomes in oncology
  - **Objective #3:** Describe the pharmacist's role in overcoming SDOH barriers
- 10:00 am – 10:20am Break
- 10:20 am – 11:30 am **Keynote: The City of Good Neighbors: Translating Buffalonian Values into Clinical Practice**  
Dr. Britny Brown, PharmD, BCOP  
Disclosed financial relationships: Research funding from Lilly

- **Objective #1:** Reflect on lived experiences that fostered a sense of belonging and inclusion
- **Objective #2:** Identify health disparities in cancer care
- **Objective #3:** Discuss strategies to advance health equity in pharmacy practice

11:30 am- 12:30 pm Lunch Break & Exhibit

12:30 - 1:00 pm **PIK Carefully: Utilization of PIK3CA Inhibitors for Treatment of Metastatic Breast Cancer**

Dr. Christina Matthews Conti, PharmD, BCOP

- **Objective #1:** Define the role of PI3K inhibition for treatment of metastatic, hormone-positive breast cancer
- **Objective #2:** Evaluate efficacy data for FDA-approved PIK3CA inhibitors (alpelisib, capivasertib & inavolisib)
- **Objective #3:** Compare toxicity profiles between FDA-approved PIK3CA inhibitors and formulate management strategies

1:00-1:30 pm **There's More to Pain Management than Oxycodone and Morphine**

Dr. Diana Violanti, PharmD, BCPS

- **Objective #1:** Calculate equianalgesic doses and identify limitations of conversion methods
- **Objective #2:** Select an appropriate buprenorphine regimen for pain management
- **Objective #3:** Describe suzetrigine's mechanism of action and place in therapy

1:30-1:50 pm Break

1:50-2:50 pm **Safe Prevention and Treatment of Cell Therapy Toxicities**

Dr. Jordan Scott, PharmD and Dr. Jordan Pleskow, PharmD

- **Objective #1:** Understand risk factors for cytokine release syndrome & neurotoxicity
- **Objective #2:** Identify preventative measures to reduce complication risks of cell therapy toxicities
- **Objective #3:** Apply treatment principles to manage toxicities of cell therapy

2:50-3:00 pm Closing Remarks  
Jordan Scott, PharmD